Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Celyad
Biotech
Stanford president resigns—Chutes & Ladders
Stanford president resigns after internal investigation. Former AbbVie strategy chief to lead Neumora. BMS poaches Pfizer neuroscience exec.
Max Bayer
,
Gabrielle Masson
Jul 21, 2023 9:30am
Cash crunches keep Bioasis and Celyad's feet to the fire
Mar 24, 2023 7:00am
By dropping remaining CAR-T, Celyad closes clinical pipeline
Dec 21, 2022 7:10am
Celyad's CAR-T cleared by FDA in phase 1 trial, details slim
Aug 1, 2022 10:17am
Moderna CFO Gomez departs after just one day—Chutes & Ladders
May 13, 2022 9:30am
Deaths spur Celyad to pause trial of off-the-shelf CAR-T therapy
Feb 28, 2022 8:15am
